Overview

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Status:
Not yet recruiting
Trial end date:
2027-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the safety, efficacy, quality of life, and biomarker response in participants with moderate to severe ulcerative colitis in clinical practice.
Phase:
Phase 4
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Ozanimod